ntla-2001
intellia therapeutics,crispr
['ntla-2001', 'cardiomyopathy', 'cardio', 'crispr']
treatment with the investigational crispr-cas9 gene-editing therapy, ntla-2001, led to rapid responses in patients with transthyretin amyloidosis with cardiomyopathy, interim phase 1 results show. #aha22 #cardiotwitter 
theheartorg | Medscape Cardiology is your best source for cardiovascular disease news online. https://t.co/Q8t8IR82zV